Aptevo reports 2023 net loss of $17.4M; cash $16.9M; AML trial plan announced

Aptevo Therapeutics Inc.

Net loss $17.4M ($1.42/share) vs 2022 net income $8.0M ($1.57/share); cash $16.9M at Dec 31, 2023.
APVO436 Phase 1b/2 frontline AML trial to start 1H24; interim data expected late 2H24; prior combo showed 91% clinical benefit rate.
ALG.APV-527 Phase 1 solid tumor trial enrolling; interim results expected 1H24.
R&D expenses fell to $17.1M (down $0.8M); G&A fell to $11.8M (down $2.1M); $9.65M gain from asset sale.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptevo Therapeutics Inc. reported financial results for year ended December 31, 2023.

Period: year ended December 31, 2023
Result: reported results

Exact text from the filing

Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-025427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.